SCOTTSDALE, Ariz., May 23 /PRNewswire/ -- MedPredict has released two companion reports designed to guide biotech and pharmaceutical decision-makers in cardiovascular therapeutic areas. The reports, one focusing on Non- Interventional Cardiology, and the other focusing on Interventional Cardiology, are based on in-depth interviews with global thought leaders following the 2008 meeting of the American College of Cardiology.
As highlighted in the Non-Interventional Cardiology report, the umbrella theme for ACC2008 was that having an effect on attributes such as BP or LDL reduction, HDL elevation and even atherosclerotic plaque burden is nice, but having an effect on a hard outcome is compelling. The subplot for the meeting was the litany of trials that didn’t quite live up to expectations. “Ironically, in the face of this disappointment it was JUPITER, a trial that wasn’t even presented, that created the most positive buzz,” according to Dr. Jeffrey Berk, the report’s primary author. In the report, the panelists also discuss the numerous combination therapy trials, appropriate endpoints for clinical trial design, and the most compelling compounds in the development pipeline.
MedPredict’s Interventional report focuses on the role of interventional and medical therapy in acute coronary syndrome. The discussion covers a broad array of stents (drug eluting vs. bare metal) and anticoagulants and their interplay in the emergency room, the cath lab, the EP lab, the orthopedic surgical theater and the post-hospital environment. Each panelist shares a perspective on the balance between restenosis, anticoagulant effects, risks of DVT/PE and bleeding. “In an era of greater restrictions on physician detailing, we also asked our panel to outline the differences they see in representatives who market drugs and devices,” said Dr. Berk. “The panel provides specific real-world examples on how hospital-based reps are influencing their prescribing behavior.”
Some of the companies discussed in these reports include Sanofi-Aventis, GlaxoSmithKline, Bristol Myers Squibb, Merck, AstraZeneca, Bayer, Johnson & Johnson, Boehringer Ingelheim, Pfizer, Astellas, Daiichi Sankyo, Novartis, Solvay, Forest, Takeda, Portola, The Medicines Company, Eli Lilly, CV Therapeutics, Trigen, Schering-Plough, Cordis, Boston Scientific, Medtronic, Abbott, Vascular Solutions, Possis, Gore, Roche, Bard.
About MedPredict
MedPredict (http://www.medpredict.com) maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. MedPredict’s reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.
CONTACT: Elizabeth Mathews of MedPredict, +1-513-271-1924,
liz@medpredict.com
Web site: http://www.medpredict.com/
